Zilucoplan SodiumProduct ingredient for Zilucoplan

Zilucoplan is a 15 amino-acid, synthetic macrocyclic peptide. It is a complement inhibitor that works to prevent the activation of C5, which is a complement protein involved in the innate immune system to initiate inflammatory responses.¹ On October 17, 2023, zilucoplan gained its first FDA approval for the treatment of generalized myasthenia gravis.⁵ It was also later approved by the EMA on December 4, 2023, as an add-on treatment for the same condition.⁷ In July 2024, it was approved by Health Canada for the same indication. ⁸